Medical device company Sedana Medical AB (publ) (SEDANA:FN Stockholm) reported on Friday a rise in demand for AnaConDa as a result of the COVID-19 pandemic and so far, with no significant supply chain disruptions although new challenges are constantly emerging.

The company expects sales increase of about 50% for the first quarter of 2020 and about 100% for the month of March, over same periods last year.

However, the company expects delay of the compilation of the IsoConDa study until the beginning of the third quarter of 2020 due to the COVID-19 pandemic. It still plans submit the application in the third or fourth of 2020 and an approval during the second half of 2021. The last patient was included in its pivotal IsoConDa study in January 2020.

COVID-19 mainly affects the lungs and for the most severely affected the consequence is lung failure (ARDS). However, studies indicate that inhaled sedation with the company's AnaConDa may be beneficial for these patients as it can reduce inflammation and increase oxygenation in the lungs. This benefit, together with inhaled sedation providing rapid awakening despite deep and long-term sedation, which is often the case for severely ill COVID-19 patients, allows patients to quickly leave intensive care and thus leave room for new patients.